ICON3 trial

Last reviewed 01/2018

The ICON3 trial compared the efficacy of:

  • an experimental treatment of carboplatin and paclitaxel, with
  • control treatment of either single agent carboplatin or CAP (cyclophosphamide, cisplatin and doxorubicin)

2074 patients with ovarian carcinoma were randomised to experimental treatment or control. The type of control treatment was decided upon by clinician and patient before randomisation. The primary endpoint was overall survival. Analysis was by intention to treat.

Reference:

The International Collaborative Ovarian Neoplasm (ICON) Group (2002). Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002; 360: 505-15

Related pages:

results

conclusions